|
[1] Salerno F, Gerbes A, Gines P, et al. Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis: a consensus workshop of the international ascites club[J]. Gut, 2007, 56:1310-1318.
|
|
[2]Martín-LlahíM, Guevara N, Torre L, et al.Prognostic im-portance of the cause of renal failure in patients with cirrhosis[J].Gastroenterology, 2011, 140 (2) :488-496.
|
|
[3]Gines A, Escorsell A, Gines P, et al.Incidence, predictive fac-tors, and prognosis of hepatorenal syndrome in cirrhosis withascites[J].Gastroenterology, 1993, 105 (1) :229-236.
|
|
[4] Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis[J]. Hepatology, 2008, 48 (6) :2064-2077.
|
|
[5]Arroya V, Bataller R, Guevara M.Treatment of hepatorenalsyndrome in cirrhosis[M].∥Arroya V, Gines P Rodes J, etal.Ascites and renal dysfunction in liver disease.BlackwellScience, 1999:492-510.
|
|
[6]Gluud LL, Christensen K, Christensen E, et al.systematicreview of randomized trials on vasoconstrictor drugs for hep-atorenal syndrome[J].Hepatology, 2010, 51 (2) :576-584.
|
|
[7]Sanyal AJ, Boyer T, Garcia-Tsao G, et al.A randomized, prospective, double-blind, placebo-controlled trial of terli-pressin for type 1 hepatorenal syndrome[J].Gastroenterolo-gy, 2008, 134 (5) :1360-1368.
|
|
[8]Martin-Llahi M, Pepin MN, Guevara M, et al.Terlipressinand albumin vs albumin in patients with cirrhosis and hepator-enal syndrome:a randomized study[J].Gastroenterology, 2008, 134 (5) :1352-1359.
|
|
[9]Wong F, Pantea L, Sniderman K.Midodrine, octreotide, albu-min, and TIPS in selected patients with cirrhosis and type 1hepatorenal syndrome[J].Hepatology, 2004, 40 (1) :55-64.
|
DownLoad: